Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 13/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 2/20 | 0.44 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MARK3 | P27448 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | BRSK2 | Q8IWQ3 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15163177 | 0.89 | TBK1 (0.51) | TBK1JAK3SYKPDPK1CDK2 | |
| SCHEMBL1284697 | 0.84 | TBK1 (0.65) | TBK1SYKULK1ULK2PDPK1 | |
| SCHEMBL1284595 | 0.83 | TBK1 (0.65) | TBK1SYKULK1ULK2PDPK1 | |
| SCHEMBL1284759 | 0.83 | TBK1 (0.67) | TBK1SYKULK1ULK2PDPK1 | |
| SCHEMBL1284951 | 0.82 | TBK1 (0.65) | TBK1SYKULK1ULK2PDPK1 | |
| SCHEMBL1285556 | 0.82 | TBK1 (0.72) | TBK1JAK3ULK1ULK2PDPK1 | |
| SCHEMBL1284415 | 0.81 | TBK1 (0.65) | TBK1JAK3CDK2MARK3IKBKE | |
| SCHEMBL1284924 | 0.81 | TBK1 (0.68) | TBK1PDPK1CDK2MARK3IKBKE | |
| SCHEMBL1284228 | 0.81 | TBK1 (0.63) | TBK1JAK3ULK1ULK2PDPK1 | |
| SCHEMBL1284746 | 0.81 | TBK1 (0.72) | TBK1ULK1ULK2PDPK1MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | TBK1 17/4885POLB 1441/4885JAK3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.